In the present study, we found that among the bulk cell product expanded ex vivo, CD8+PD-1+ T cells could be identified as tumor-reactive, and their expansion correlated with the breadth of TCR Clonality and clinical outcome of patients treated with ACT. The gene discussed is CD8A; the disease is neoplasm.